| Literature DB >> 28272301 |
Ming Xu1, Min Xu2, Lei Han3, Chao Yuan4, Yong Mei5, Hengdong Zhang6, Shi Chen7, Kai Sun8, Baoli Zhu9.
Abstract
The superoxide dismutase 2 (SOD2) gene is a pivotal part of oxidative stress system, which could induce the onset of pulmonary arterial hypertension (PAH). In this study, we quantified the influence of a SOD2exonic polymorphism (rs4880) on PAH susceptibility. We genotyped this single nucleotide polymorphism (SNP) by TaqMan, and evaluated its association with PAH susceptibility in a case-control study of 460 patients and 530 controls in China. There were significant differences between PAH cases and controls in both CC and TC+CC genotypes (p = 0.013 and p = 0.010, respectively). Furthermore, the number of variant alleles followed a dose-response manner (p trend was 0.023). Besides, the mRNA level and protein expression also indicated that the C allele of this variant decreased the expression of SOD2 gene (p = 0.004 in mRNA level and p = 0.012 in protein level) after the transfection of plasmids containing the different genotype of rs4480. There is significant association between SOD rs4880 polymorphism and the PAH susceptibility, and this polymorphism influenced PAH susceptibility by altering the expression of SOD2.Entities:
Keywords: SOD2; exonic polymorphism; pulmonary arterial hypertension; susceptibility
Mesh:
Substances:
Year: 2017 PMID: 28272301 PMCID: PMC5369102 DOI: 10.3390/ijerph14030266
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Demographic and hemodynamic characteristics of PAH patients (case) and normal subjects (control).
| Variables | Case ( | Control ( | |
|---|---|---|---|
| age (years) | 44.6 ± 13.9 | 45.4 ± 13.6 | 0.861 |
| sex | 0.853 | ||
| male | 135 (29.3%) | 163 (30.8%) | |
| female | 325 (70.7%) | 367 (69.2%) | |
| BMI (kg/m2) | 25.6 ± 4.5 | 25.1 ± 5.3 | 0.399 |
| 6MWD (m) | 247.9 (146.2–363.3) | ||
| NT-proBNP (pg/mL) | 1139.9 (360.9–2471.8) | ||
| mPAP (mmHg) | 51 (40–59) | ||
| PVRI (dyn*sec*m2/cm5) | 1485.2 (1137.3–2742.7) | ||
| CO (L/min) | 3.86 ± 1.81 | ||
| CI (L/min/m2) | 2.23 ± 0.88 |
Data are presented as mean ± SD or median (interquartile range). BMI: body mass index; 6MWD: 6-min walk distance; NT-proBNP: N-terminal pro brain natriuretic peptide; mPAP: mean pulmonary arterial pressure; PVRI: pulmonary vascular resistance index; CO: cardiac output; CI: cardiac index.
Genotype frequencies of SOD2 rs4880 polymorphism in PAH cases and controls.
| rs4880 T > C | Cases, | Controls, | OR (95% CI) a | |
|---|---|---|---|---|
| TT | 319 (69.35%) | 426 (80.37%) | Reference | - |
| TC | 111 (24.13%) | 99 (18.68%) | 1.35 (0.79–2.81) | 0.195 |
| CC | 30 (6.52%) | 5 (0.94%) | 3.81 (1.22–5.67) | 0.013 |
| TC + CC | 141 (30.65%) | 104 (19.62%) | 2.75 (1.23–3.98) | 0.010 |
| 0.023 |
a adjusted for age and sex in additive model in logistic regression.
Stratified analyses of SOD2 rs4880 polymorphism associated with the PAH clinical features by genetic dominant model.
| Variables | Case ( | ||
|---|---|---|---|
| TT ( | TC + CC ( | ||
| 6MWD (m) | 258.7 ± 49.6 | 239.2 ± 41.3 | 0.001 |
| NT-proBNP (pg/mL) | 1075.7 ± 256.5 | 1177.8 ± 243.4 | <0.001 |
| mPAP (mmHg) | 50 ± 5 | 52 ± 7 | <0.001 |
| PVRI (dyn*sec*m2/cm5) | 1461.6 ± 252.9 | 1516.0 ± 274.2 | 0.063 b |
| CO (L/min) | 4.01 ± 1.84 | 3.58 ± 1.73 | 0.021 |
| CI (L/min/m2) | 2.36 ± 0.79 | 2.18 ± 0.91 | 0.035 |
a Adjusted for age, sex, and BMI in logistic regression model. b Non-parametric test were performed for PVRI.
Figure 1SOD2 expression levels of rs4880 different variants. (A) SOD2 mRNA expression; (B) SOD2 protein expression; (C) Gray scale analysis of (B).